Dr?gerwerk AG & Co. KGaA: Business development in the first half year significantly above prior year despite lower earnings in the second quarter
Ad-hoc notification in accordance with Sec. 17 of the MAR
Dr?gerwerk AG & Co. KGaA: Business development in the first half year significantly above prior year despite lower earnings in the second quarter L?beck, July 14, 2021
In the first half of 2021, Dr?ger's net sales and earnings were significantly above the prior-year figures. Based on preliminary business figures, the Group's net sales increased currency-adjusted by 17.3 percent (nominal 14.3 percent) to around EUR 1,633 million (6 months 2020: EUR 1,428.4 million). At around EUR 209 million, EBIT generated in the first half of the year was significantly higher than in the previous year (6 months 2020: EUR 102 million).
At around EUR 738 million order entry in the second quarter was at a similarly high level as in the first three months of the year (Q1 2021: EUR 739.8 million) due to the continuing high demand in connection with the coronavirus pandemic. Net sales were around EUR 841 million, a currency-adjusted increase of 9.0 percent (nominal: 6.7 percent) compared to the prior year's period (Q2 2020: EUR 788.4 million). EBIT came out below the level of the previous year at around EUR 80 million (Q2 2020: EUR 102 million). This was due to the lower gross margin of around 46 percent (Q2 2020: 49.2 percent) and higher functional expenses.
Due to the better than expected order development, Dr?ger had already raised its guidance on June 21. Following the record year 2020, management expects the Dr?ger Group's net sales to decline currency-adjusted by between -2.0 and -6.0 percent (nominal: -3.0 to -7.0 percent) in the current fiscal year. The EBIT margin is expected to be between 8.0 and 11.0 percent. Dr?ger expects pandemic-related demand to normalize in the second half of the year and does not anticipate comparable demand in the coming year.
Dr?ger will publish its full results for the first six months of the fiscal year on July 29, 2021.
Dr?gerwerk AG & Co. KGaA Moislinger Allee 53-55 23558 L?beck, Deutschland www.draeger.com
Investor Relations: Thomas Fischler Tel. +49 451 882-2685 firstname.lastname@example.org
Corporate Communications: Melanie Kamann Tel. +49 451 882-3998 email@example.com
Disclaimer This ad hoc report contains statements on the future development of Dr?ger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dr?ger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dr?ger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.
14-Jul-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: Dr?gerwerk AG & Co. KGaA Moislinger Allee 53-55 23542 L?beck
Germany Phone: +49 (0)451 882-0 Fax: +49 (0)451 882-2080 E-mail: firstname.lastname@example.org Internet: www.draeger.com ISIN: DE0005550602, DE 000 555 063 6, DE 000 555 065 1, DE 000 555 067 7, DE 000 555 071 9 WKN: 555060, 555063 Vorz?ge, 555065 Genussschein A, 555067 Genussschein K, 555071 Genussschein D Indices: TecDAX Listed: Regulated Market in Berlin, Frankfurt (Prime Standard), Hamburg, Hanover; Regulated Unofficial Market in Stuttgart, Tradegate Exchange EQS News ID: 1218946 ? End of Announcement DGAP News Service